Acne Vulgaris: Nuances in the Approach to Treatment in Patients with Darker Skin Tones
At the 2021 Skin of Color Update virtual conference, Dr. Alexis highlighted key considerations when treating acne in patients with darker skin phototypes in addition to current and emerging strategies to improve treatment outcomes.
When treating acne patients with skin of color, it is important to consider the concomitant issue of post inflammatory hyperpigmentation (PIH). This PIH may be the d …
At the 2021 Skin of Color Update virtual conference, Dr. Alexis highlighted key considerations when treating acne in patients with darker skin phototypes in addition to current and emerging strategies to improve treatment outcomes.
When treating acne patients with skin of color, it is important to consider the concomitant issue of post inflammatory hyperpigmentation (PIH). This PIH may be the d … 
2021 is the 50th anniversary of the FDA approval of minocycline (MCN). While many other antibiotics have become obsolete during this time, MCN continues to be quite useful. In dermatology, MCN is used prominently in acne vulgaris, and is also employed in many other dermatological conditions because of its molecular and pharmacological properties. In this article, we review the history of minocycli … 
This patient also has a diagnosis of acne vulgaris (diagnosed 10 years ago). What is the most likely explanation for these cutaneous changes?
A. Peripheral vascular disease
B. Diabetes mellitus
C. Drugs hypersensitivity reaction to penicillin
D. Minocycline-induced hyperpigmentation
E. Leukocytoclastic vasculitis
To find out the correct answer and read the explanation, click he … 
The June issue of the Journal of Drugs in Dermatology focuses on the topics of acne and rosacea, and features additional articles on topics such as atopic dermatitis and psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
Guest Editor James Q. Del Rosso discusses roadblocks that impede patient ability to obtain medications selected by their dermatologist … 
Case Scenario
A 26-year-old patient presents to the dermatology clinic with severe nodulocystic scarring acne. The patient identifies as a transgender male and notes that he has been receiving hormone replacement therapy for the past 4 years with weekly intramuscular testosterone injections. He has not had any gender-affirming surgeries and reports being currently amenorrhoeic. He is curren … 